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Purpose: To describe a case of choroidal osteoma with choroidal neovascularization (CNV) 
that was successfully treated with two intravitreal injections of bevacizumab (IVB).
Design and methods: Case report on a 12-year-old Japanese girl who presented with a sud-
den decrease in vision in her left eye. At the first visit, 2 days after the onset of her symptoms, 
her visual acuity (VA) in her left eye was 0.2. Ophthalmoscopy showed a hemorrhage of 5 disc 
diameters under the retinal pigment epithelium and a serous retinal detachment at the posterior 
pole of the left eye. These findings were confirmed by optical coherence tomography. Fluorescein 
angiography (FA) and indocyanine green angiography (ICGA) showed several points of leakage 
around the fovea, which suggested a CNV . From these findings, the patient was diagnosed with 
choroidal osteoma with a CNV . The submacular hemorrhage was from the CNV associated 
with the choroidal osteoma. We treated her with two injections of 1.25 mg/0.05 mL IVB with 
a 4-month interval.
Results: The patient’s VA in her left eye improved to 0.7, and this vision was maintained for 
4 years. The CNV disappeared in the FA and ICGA images and no recurrence was observed 
after 4 years.
Conclusion: Our findings indicate that IVB is effective in resolving CNV in eyes with an 
osteoma and prevents a decrease of vision in eyes with a choroidal osteoma with a CNV .
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Introduction
A choroidal osteoma is a rare and benign choroidal tumor, and its clinical and histo-
pathological features were first reported by Gass et al.1 Choroidal osteomata are seen 
in the peripapillary and macular areas of young healthy girls. The striking features of 
a choroidal ostroma are: well defined mass; slightly elevated, white-to-cream or orange 
lesion as observed by ophthalmoscopy; and high tissue density due to calcification as 
observed by ultrasonography and computed tomography (CT).
Choroidal osteomata usually grow very slowly, but some patients have an acute 
decrease in vision. The main causes of this sudden decrease in vision are a serous 
macular detachment or a subretinal hemorrhage, with or without choroidal neovascu-
larization (CNV). A definitive treatment for the CNV associated with a choroidal 
osteoma has not been established. Photocoagulation,2,3 surgical removal of the CNV ,4 
photodynamic therapy (PDT),5–7 and transpupillary thermotherapy (TTT)8,9 have been 
tried, but long-term vision is usually not well preserved.
Intravitreal injections of vascular endothelial growth factor (VEGF) antibody 
(eg, bevacizumab) has been used to block the activity of VEGF in eyes with a CNV Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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  associated with age-related macular degeneration (AMD). 
This therapy has reduced the visual loss and improved visual 
acuity (VA). Bevacizumab is a full-length VEGF antibody 
that has been used for off-label treatment of CNVs associated 
with neovascular AMD.10
Earlier studies have shown that intravitreal bevacizumab 
(IVB) was effective in resolving the CNV associated with a 
choroidal osteoma.11–13 But the follow-up periods in these 
reports were short; that is, from 4 to 10 months.
We report a case of choroidal osteoma with a CNV that 
was successfully treated with two injections of IVB, and 
good vision has been maintained for at least 4 years.
Case report
A 12-year-old Japanese girl presented with a sudden 
decrease of vision in her left eye on November 13, 2006. 
Her systemic and ophthalmological histories were not 
significant. At her first visit, 2 days after the onset, her 
VAs were 1.2 OD and 0.2 OS. The intraocular pressures 
were within the normal limits in both eyes. Slit-lamp 
  biomicroscopy showed no remarkable changes, including 
the absence of inflammation of the anterior segments. 
Ophthalmoscopy showed a 5-disc diameter hemorrhage 
under the retinal pigment epithelium (RPE) and serous 
retinal detachment (SRD) at the posterior pole of the left 
eye (Figure 1A). These findings were confirmed by optic 
coherence tomography (OCT) (Figure 1B). Fluorescein 
angiography (FA) showed a mild pooling of dye associated 
with a pigment epithelium detachment and several points 
of leakage superior and inferior to the fovea (Figure 1C). 
Indocyanine green angiography (ICGA) showed leakage 
lateral and inferior to the fovea, which suggested a CNV 
(Figure 1D). The ophthalmoscopic, OCT, FA, and ICGA 
findings were normal in the right eye.
CT showed calcification and a bone-density mass in the 
posterior pole of the left eye (Figure 2A), but magnetic reso-
nance imaging showed no unusual changes in the intra- and 
extraocular areas. Ultrasound echography (B-mode) showed 
a flat convex elevation in the posterior pole of the eye, which 
produced an acoustic shadow behind the sclera (Figure 2B). 
A
B
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Figure 1 Patient with a choroidal osteoma and choroidal neovascularization before treatment. (A) Fundus photograph showing 5-disc-diameter hemorrhage under the 
retinal pigment epithelium. (B) Horizontal optical coherence tomographic image, showing pigment epithelial detachment and serous retinal detachment. (C, D) Angiography: 
fluorescein angiography (C) and indocyanine angiography (D) show several points of dye leakage around the fovea.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1053
Intravitreal bevacizumab for CNV associated with choroidal osteoma
Microperimetry showed poor sensitivity with poor focus and 
fixation (Figure 4A). The serological examinations were 
negative.
On the basis of these findings, the patient was diagnosed 
with choroidal osteoma and the submacular hemorrhage was 
from a CNV associated with the choroidal osteoma. We treated 
her with 1.25 mg/0.05 mL injection of IVB (Avastin®; 
  Genentech, South San Francisco, CA) after obtaining approval 
from the Institutional Review Board of Chiba University. 
Approval was also obtained from the patient and her parents.
The subretinal fluid quickly disappeared 8 days after this 
treatment, and the elevation of the RPE disappeared. 
Two months later, her VA improved to 0.6 OS, and the size 
of the dye leakage was reduced, although not completely. 
We gave a second IVB injection 4 months after the first 
treatment, the CNV disappeared, and no recurrence has been 
observed (Figure 3).
The patient was followed for 4 years, and microperimetry 
showed that the average sensitivities improved from 8.0 dB 
before, to 6.0 dB at 4 months, 4.8 dB at 6 months, and 10.0 dB 
at 42 months after the IVB (Figure 4B). At 4 years, her VA 
remained good at 0.7 OS.
Discussion
A choroidal osteoma is mostly found in healthy young women. 
Alyward et al reported that 89% of patients with a choroidal 
osteoma were women with a mean age of 21 years.2 This tumor 
is usually slow growing but can grow rapidly in some cases.14 
One study reported that the VA decreased in 26% of the cases 
at 5 years and 45% at 10 years.15 In another study, the VA 
decreased to #0.1 in 45% of the cases at 5 years, 56%–58% 
at 10 years, and 62% at 20 years.2,15
Thus, there is a slow but progressive decrease of vision 
in eyes with choroidal osteoma, even those treated with 
photocoagulation.
The long-term visual prognosis of a choroidal osteoma 
is not good. The decrease in vision is due to SRD, CNV , 
A B
Figure 2 (A) Computed tomographic images of patient with choroidal osteoma, 
showing calcification and bone-density mass in the posterior pole of the left eye. 
(B) Ultrasonic echography (B-mode) shows a convex elevation in the posterior pole 
of the eye, producing an acoustic shadow behind the sclera.
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Figure 3 Patient with a choroidal osteoma and choroidal neovascularization 18 months after two intravitreal injections of bevacizumab. Fundus photograph (A), horizontal optical 
coherence tomographic scan (B), fluorescein angiography    indocyanine angiography (C), and indocyanine angiography (D) all show absence of subretinal fluid and leakage points.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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atrophy of the RPE, or a combination of these. A CNV was 
found in 31% of the cases at 5 years, 31%–47% at 10 years, 
and 56% at 20 years.2,15
There is no standard treatment for a choroidal osteoma. 
Various treatments for CNV have been tried, but the treatments 
do not usually stop the vision decrease. The results of one study 
showed that photocoagulation of an extrafoveal classic CNV 
was successful in 25% of the cases, and the neovascular mem-
brane was eliminated.2 However, photocoagulation can stimu-
late rapid vascular remodeling and anastomoses in choroidal 
osteoma.3 Another study reported that the CNV can be surgi-
cally removed, but the postoperative VA was poor at 0.06.4
PDT has been partially successful in treating CNV in 
eyes with choroidal osteoma. Earlier studies show that 
6 months after a single PDT the metamorphopsia can resolve 
completely; in one study the visual acuity was not changed5 
and in another study it even improved from 0.1 to 1.0.6 
Another study reported that four PDT applications obstructed 
the CNV completely, but the final VA was 0.17.7
TTT was effective in obstructing the CNV but the visual 
outcome was also poor. An earlier report indicates that at 
10 months after one TTT application, the VA improved from 
0.25 to 0.33, and the vision was maintained with a scarred 
CNV .8 In another report, the final VA was 0.1 after three 
TTT applications.9
The cause for the development of a CNV in eyes with a 
choroidal osteoma has not been determined, but it has been 
hypothesized that tumors with overlying hemorrhage and 
irregular surface were at greater risk of developing a CNV .15 
Because of the long duration of the tumor, the normal tissue 
may be slightly damaged. In addition, the mild ischemic 
stress and chronic inflammation of the choroidal membrane 
and the retina may upregulate the expression of VEGF. The 
disruption of the RPE and thinning or loss of the Bruch 
membrane and choriocapillaris might also contribute to the 
development of a CNV . A thin, degenerated RPE overlying 
the osteoma allows the growth of new abnormal vessels 
stimulated by VEGF. Therefore anti-VEGF therapy may be 
effective under such pathological conditions.
The results of recent studies have suggested that IVB is 
a good treatment for reducing CNV of choroidal osteomata, 
with improvements in VA. For example, the VA improved 
from 0.1 to 0.8 nine months after one injection,11 and from 
finger counting to 0.16 at 4 months after two injections.12 In 
another study, the vision improved from finger counting to 
0.1 ten months after two injections of IVB.13 In these three 
reports, the effects of bevacizumab were followed for 
4–10 months. In our case, the effects of bevacizumab 
remained stable for over 4 years.
In our case, the average MP1-determined sensitivities 
improved from 8.0 dB before to 6.0 dB at 4 months and to 
4.8 dB at 6 months after the IVBs. But the average sensitivi-
ties decreased to 10.0 dB at 42 months after the IVBs, which 
was most likely because the retinal sensitivity of the inferior 
nasal side probably decreased to lower the average   sensitivity. 
RPE atrophy occurred in the inferior nasal region of the 
macula, and the fovea was not affected. This is why the VA 
remained good even after the retinal sensitivity decreased. 
Thus, this disagreement between VA and retinal sensitivity 
may not be too surprising in some cases. Because the fundus 
and FA findings showed marked RPE atrophy in the nasal 
inferior of the retina, the retinal sensitivity of the nasal infe-
rior area could not be improved.
In conclusion, we report a case of choroidal osteoma with 
a CNV that was successfully treated with two injections of 
IVB. The vision was maintained at 0.7 for at least 4 years. 
Our findings indicate that intravitreal injections of bevaci-
zumab may be effective in preventing vision decrease in eyes 
with a choroidal osteoma with a CNV .
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